Can the genetic makeup of their cancers predict how patients with lung cancer will respond to radiation therapy? And can this information be used to advance a genetically guided strategy for patients with these tumors? Cleveland Clinic researcher and radiation oncologist Mohamed Abazeed, M.D., Ph.D., has been awarded a $2 million grant from the National Cancer Institute (NCI) to delve into those and other related questions.